| How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% |
The average of price targets set by Wall Street analysts indicates a potential upside of 258.3% in Spyre Therapeutics (SYRE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-05-13 15:00:54 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is well tolerated, has a pharmacokinetic ("PK") profile enabling quarterly or biannual dosing, and provides complete target engagement at expected Phase 2 trough concentrations Remain on track to report interim Phase 1 data for SPY002 later this quarter, with the potential to demonstrate a product profile superior to first-generation TL1A antibodies Announced first participant dosed in Phase 1 trial of SPY003, with interim PK and safety data readout on track for the second half of 2025 $565 million of cash, cash equivalents, and marketable securities as of March 31, 2025, with expected runway into the second half of 2028 WALTHAM, Mass. , May 8, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD") and other immune-mediated diseases, today announced its first quarter 2025 financial results and provided program and corporate updates. |
prnewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 |
SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) SPY001 pharmacokinetic (PK) data up to eight months continues to support a potential best-in-class profile, including a half-life more than three times that of vedolizumab SPY001 pharmacodynamic (PD) data up to eight months showed that a single dose of SPY001 resulted in rapid and sustained saturation of α4β7 receptors at expected Phase 2 trough concentrations Spyre remains on track to initiate its planned platform Phase 2 trial in mid-2025 that includes SPY001, followed by SPY002 (TL1A), SPY003 (IL-23), and combinations thereof, with initial monotherapy data expected in 2026 WALTHAM, Mass. , May 5, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced two poster presentations at Digestive Disease Week (DDW) 2025, being held May 3-6, 2025, in San Diego, California. |
prnewswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces Grants of Inducement Awards |
WALTHAM, Mass. , May 2, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 64,400 shares of common stock of Spyre to seven non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). |
prnewswire.com |
2025-05-02 20:05:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces Grants of Inducement Awards |
WALTHAM, Mass. , April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 93,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). |
prnewswire.com |
2025-04-04 20:05:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody |
Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025 Subject to interim results, Spyre expects to incorporate SPY003 into its planned Phase2 study in ulcerative colitis exploring six investigational monotherapies andcombinations WALTHAM, Mass. , March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003. |
prnewswire.com |
2025-03-27 18:05:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces Grants of Inducement Awards |
WALTHAM, Mass. , March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 132,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). |
prnewswire.com |
2025-03-07 18:40:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics: Targeting The Future Of IBD Treatment |
Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis. |
seekingalpha.com |
2025-03-04 06:51:30 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million public offering Continued execution towards expected milestones across portfolio, with interim Phase 1 data readouts for SPY002 and SPY003 on-track for the second quarter and second half of 2025, respectively Remain on track for initiation of Phase 2 platform trial in ulcerative colitis ("UC") in mid-2025 with SPY001 (α4β7), followed by SPY002 (TL1A), SPY003 (IL-23), and combinations thereof, with initial monotherapy results expected in 2026 Announced indication expansion into rheumatoid arthritis ("RA") with SPY002, with expected Phase 2 trial initiation in mid-2025 and top-line results in 2026 $603 million of cash, cash equivalents, and marketable securities as of December 31, 2024, with expected runway into the second half of 2028 WALTHAM, Mass. , Feb. 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD") and other immune-mediated diseases, today announced its fourth quarter and full year 2024 financial results and provided program and corporate updates. |
prnewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics to Participate in Upcoming March Investor Conferences |
WALTHAM, Mass. , Feb. 25, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences: Event: TD Cowen 45th Annual Healthcare Conference Format: Fireside chat and 1x1 meetings Date/Time: Tuesday, March 4, 2025 at 3:10pm ET Location: Boston, MA Event: Jefferies Biotech on the Beach Summit Format: 1x1 meetings Date: Tuesday, March 11, 2025 Location: Miami, FL Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations. |
prnewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation |
WALTHAM, Mass. , Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates (NHPs). |
prnewswire.com |
2025-02-19 10:00:00 |
Czytaj oryginał (ang.) |
| Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? |
The consensus price target hints at a 158.9% upside potential for Spyre Therapeutics (SYRE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-02-10 12:56:09 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces Grants of Inducement Awards |
WALTHAM, Mass. , Feb. 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 35,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). |
prnewswire.com |
2025-02-07 19:13:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-05 17:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-04 19:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-01 12:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-30 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-28 14:10:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-26 14:00:00 |
Czytaj oryginał (ang.) |
| ATTENTION SYRE SHAREHOLDERS: Investors who Lost Money on Spyre Therapeutics, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation |
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spyre Therapeutics, Inc. ("Spyre Therapeutics, Inc.") (NASDAQ:SYRE) concerning possible violations of federal securities laws. On November 18, 2024, Spyre disclosed in a filing with the U.S. Securities and Exchange Commission "that the Company's previously issued audited consolidated financial statements as of December 31, 2023 and for the year and the second and third quarter interim periods within the year then ended, and its unaudited consolidated financial statements for the quarterly and year-to-date (as applicable) periods ended March 31, 2024, June 30, 2024 and 2023, and September 30, 2024 and 2023 (collectively, the ‘Affected Financial Statements' and such periods, the ‘Affected Periods') should no longer be relied upon" due to "a misapplication of Generally Accepted Accounting Principles in the United States. |
accessnewswire.com |
2025-01-24 15:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-24 14:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Spyre Therapeutics, Inc. (SYRE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK CITY, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spyre Therapeutics, Inc. ("Spyre Therapeutics, Inc.") (NASDAQ:SYRE) concerning possible violations of federal securities laws. On November 18, 2024, Spyre disclosed in a filing with the U.S. Securities and Exchange Commission "that the Company's previously issued audited consolidated financial statements as of December 31, 2023 and for the year and the second and third quarter interim periods within the year then ended, and its unaudited consolidated financial statements for the quarterly and year-to-date (as applicable) periods ended March 31, 2024, June 30, 2024 and 2023, and September 30, 2024 and 2023 (collectively, the ‘Affected Financial Statements' and such periods, the ‘Affected Periods') should no longer be relied upon" due to "a misapplication of Generally Accepted Accounting Principles in the United States. |
accessnewswire.com |
2025-01-23 13:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-22 17:45:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-21 21:10:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-18 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-16 22:00:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts |
Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025 Phase 2 platform trial in ulcerative colitis (UC) remains on track for initiation in mid-2025 with SPY001 (α4β7), followed by SPY002 (TL1A), SPY003 (IL-23), and combinations thereof, with initial results expected in 2026 Announces indication expansion into rheumatoid arthritis (RA) with SPY002; Phase 2 RA trial initiation anticipated in mid-2025 with topline results in 2026 Strong balance sheet with preliminary cash, cash equivalents, and marketable securities balance of over $600M as of December 31, 2024*, anticipated to provide cash runway into the second half of 2028 WALTHAM, Mass. , Jan. 13, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today highlighted its 2025 priorities, including: upcoming first-in-human clinical data for SPY002 and SPY003, an indication expansion of its SPY002 program into RA, and a plan to deliver four clinical proof-of-concept readouts in 2026. |
prnewswire.com |
2025-01-13 10:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-10 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-04 14:00:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Announces Grants of Inducement Awards |
WALTHAM, Mass. , Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 21,000 shares of common stock of Spyre to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). |
prnewswire.com |
2025-01-03 19:20:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-03 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-02 12:55:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-31 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-30 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-29 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-12-27 19:10:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-26 18:50:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-24 17:45:00 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics Added to the Nasdaq Biotechnology Index |
WALTHAM, Mass. , Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced Spyre has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open, Monday, December 23, 2024. |
prnewswire.com |
2024-12-18 10:00:00 |
Czytaj oryginał (ang.) |
| TD says Spyre has 'superior TL1A program' after Teva data |
TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to its bigger rivals, Spyre has an anti-TL1A monoclonal antibody in its product pipeline, known as SPY002, the analyst tells investors in a research note. TD believes Spyre has the "superior TL1A program" and its combination treatments under development "will further elevate outcomes." Teva and Sanofi's results "further validate TL1A inhibition as a highly promising mechanism" for both ulcerative colitis and Crohn's disease, contends the firm. Spyre Therapeutics +0.105 (+0.43%) Teva +4.32 (+26.18%) Sanofi +3.38 (+7.37%) |
https://thefly.com |
2024-12-17 16:18:32 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG |
BTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in development and launch milestones. The firm's "main takeaways" for Spyre Therapeutics (SYRE) from today's update from Teva are that strong market demand for anti-TL1A assets has "not faded at all" and the upside potential for SPY002 "looks even further reinforced," as BTIG expects the TL1A constructs that Spyre is developing to "likely leapfrog the broader class both on efficacy and dosing." The firm, which keeps a Buy rating and $70 price target on Spyre shares, views the relative weakness following the duvakitug data as a buying opportunity, the analyst tells investors. Spyre Therapeutics -0.005 (-0.02%) Teva +4.385 (+26.58%) |
https://thefly.com |
2024-12-17 16:03:04 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NK / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-17 13:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-16 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-15 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-13 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE |
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-11 16:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE. |
accesswire.com |
2024-12-04 12:00:00 |
Czytaj oryginał (ang.) |
| SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE) on behalf of Spyre stockholders. Our investigation concerns whether Spyre has violated the federal securities laws and/or engaged in other unlawful business practices. |
globenewswire.com |
2024-12-03 23:00:00 |
Czytaj oryginał (ang.) |